PDF herunterladen
Pharmacopsychiatry 2003; 36(3): 105-112
DOI: 10.1055/s-2003-39985
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Schizophrenic Patients’ Subjective Reasons for Compliance and Noncompliance with Neuroleptic Treatment

W. Löffler1 , R. Kilian1 , M. Toumi2 , M. C. Angermeyer1
  • 1Universtity of Leipzig, Department of Psychiatry, Leipzig, Germany
  • 2H. Lundbeck A/S, Department of Pharma Economics, Valby-Copenhagen, Denmark
The base study was funded by grants from the German Federal Ministry of Education and Research in the framework of the research association public health Saxony (grant no. 01EG9732/7). The second part of the study was funded by H. Lundbeck A/S.
Weitere Informationen

Publikationsverlauf

Received: 15.11.2001 Revised: 23.7.2002

Accepted: 27.8.2002

Publikationsdatum:
13. Juni 2003 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Although several factors influencing schizophrenic patients’ compliance with neuroleptic treatment have been investigated, the subjective reasons that patients are willing or reluctant to take medication have rarely been examined. In a follow-up study of a sample of schizophrenic patients currently undergoing psychiatric treatment in the city of Leipzig, 307 patients were asked about their subjective reasons for medication compliance or noncompliance by administering the Rating of Medication Influences (ROMI) Scale. The perceived benefit from medication proved to be the main reason for patients’ compliance with neuroleptic treatment. Respectively, patient-reported noncompliance was mainly explained by negative side effects of medication. However, there were no statistically significant differences in responses between the patients receiving conventional versus second-generation antipsychotics. A positive relationship with the therapist and a positive attitude of significant others toward neuroleptic treatment contributed to patients’ medication compliance. Reasons for noncompliance with neuroleptic treatment were lack of acceptance of the necessity of pharmacological treatment and lack of insight into the disease. The results emphasize the importance of psychoeducation in enhancing patient compliance with neuroleptic treatment.

References

  • 1 Agarwal M R, Sharma V K, Kishore Kumar K V, Lowe D. Noncompliance with treatment in patients suffering from schizophrenia: A study to evaluate possible contributing factors.  International Journal of Social Psychiatry. 1998;  44(2) 92-106
    PubMedGoogle Scholar
  • 2 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM IIIR) 3d ed. Washington DC; APA 1994
    Google Scholar
  • 3 Angermeyer M C, Löffler W, Müller P, Schulze B, Priebe S. Patients’ and relatives’ assessment of clozapine treatment.  Psychol Med. 2001;  31 509-517
    PubMedGoogle Scholar
  • 4 Angermeyer M C, Matschinger H. Neuroleptika und Lebensqualität.  Psychiatr Prax. 2000;  27 64-68
    PubMedGoogle Scholar
  • 5 Angermeyer M C, Matschinger H. Public attitude towards psychiatric treatment.  Acta Psychiatr Scand. 1996;  94 326-336
    PubMedGoogle Scholar
  • 6 Awad A G. Subjective response to neuroleptics in schizophrenia.  Schizophrenia Bulletin. 1993;  19 609-618
    PubMedGoogle Scholar
  • 7 Awad A G, Hogan T P, Voruganti L NP, Heslegraves R J. Patients’ subjective experiences on antipsychotic medications: implications for outcome and quality of life.  International Clinical Pharmacology. 1995;  10 123-132
    PubMedGoogle Scholar
  • 8 Barnas C, Hummer M, Fleischhacker W W. Compliance Probleme bei der Behandlung schizophrener Patienten.  Wiener Medizinische Wochenschrift. 1998;  11 281-283
    PubMedGoogle Scholar
  • 9 Benkert O, Kepplinger H M, Sobota K. Psychopharmaka im Widerstreit. Berlin; Springer 1995
    Google Scholar
  • 10 Bollen K A, Lennox R. Conventional wisdom on measurement: A structural equation perspective.  Psychol Bull. 1991;  110(2) 305-314
    CrossrefPubMedGoogle Scholar
  • 11 Buchanan A. Treatment complicane in schizophrenia.  Advances in Psychiatric Treatment. 1998;  4 227-234
    PubMedGoogle Scholar
  • 12 Cabeza I G, Amador M S, Lopez C A, de Chavez M G. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors.  Schizophr Res. 2000;  41 349-355
    CrossrefPubMedGoogle Scholar
  • 13 Chacos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: Areview and meta-analysis of randomized trials.  American Journal of Psychiatry. 2001;  158 518-526
    CrossrefPubMedGoogle Scholar
  • 14 Chisholm D, Knapp M RJ, Knudson H C, Amaddeo F, Gaite L, vanWijngaarden B. Client Sociodemographic and Service Receipt Inventory - European Version.  Br J Psychiatry. 2000;  17 (suppl. 39) 28-33
    PubMedGoogle Scholar
  • 15 Day J C, Kinderman P, Bentall R. A comparison of patients’ and prescribers’ beliefs about neuroleptic side effects: prevalence, distress and causation.  Acta Psychiatr Scand. 1998;  97 93-97
    PubMedGoogle Scholar
  • 16 Dolder C R, Lacro J P, Dunn L B, Jeste D V. Antipsychotic medication adherence: Is there a difference between typical and atypical agents?.  American Journal of Psychiatry. 2002;  159 103-108
    CrossrefPubMedGoogle Scholar
  • 17 Fayers P M, Hand D J. Factor analysis, causal indicators and quality of life.  Qual Life Res. 1997;  6(2) 39-150
    PubMedGoogle Scholar
  • 18 Fenton W S, Blyler C R, Heinssen R K. Determinants of medication compliance in schizophrenia: Empirical and clinical findings.  Schizophr Bull. 1997;  23(4) 637-651
    Google Scholar
  • 19 Fleiss J L. Statistical methods for rates and proportions. New York; John Wiley & Sons 1981
    Google Scholar
  • 20 Garcia Cabeza I, Sanz Amador M, Arango Lopez C, Gonzalez de Chavez M. Subjective response to antipsychotics in schizophrenia patients: clinical implications and related factors.  Schizophr Res. 2000;  41 349-355
    CrossrefPubMedGoogle Scholar
  • 21 Glick I D, Berg P H. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.  International Clinical Psychopharmacology. 2002;  17 65-68
    PubMedGoogle Scholar
  • 22 Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker W W. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia.  Journal of Clinical Psychiatry. 2002;  63 49-53
    PubMedGoogle Scholar
  • 23 Hogan T P, Awad A G, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity.  Psychological Medicine. 1983;  13 177-183
    PubMedGoogle Scholar
  • 24 Hornung W P, Feldmann R, Schonauer K, Schafer A, Monking H S, Klingberg S. et al . Psychoedukativ-psychotherapeutische Behandlung von schizophrenen Patienten und ihren Bezugspersonen. II. Ergänzende Befunde der 2-Jahres-Katamnese.  Nervenarzt. 1999;  70(5) 444-449
    CrossrefPubMedGoogle Scholar
  • 25 Kampman O, Lehtinen K. Compliance in psychoses.  Acta Psychiatr Scand. 1999;  100(3) 67-175
    Google Scholar
  • 26 Kampman O, Lethinen K, Lassila V, Leinonen E, Poutanen O, Koivisto A -M. Attitudes toward neuroleptic treatment: Realiability and validity of the Attitudes towards Neuroleptics Treatment (ANT) questionaire.  Schizophr Res. 2000;  45 223-234
    CrossrefPubMedGoogle Scholar
  • 27 Kilian R, Lindenbach I, Angermeyer M C. ”(...) manchmal zweifle ich an mir, wenn es mir nicht gut geht” - Die Wirkung eines ambulanten psychoedukativen Gruppenprogramms aus der subjektiven Perspektive von Patienten mit schizophrenen Erkrankungen.  Psychiatr Prax. 2001;  28(4) 57-206
    PubMedGoogle Scholar
  • 28 Kilian R, Roick C, Bernert S, Morry C, Matschinger H, Becker T. et al . Die europäische Standardisierung und die deutschsprachige Adaptation von Instrumenten zur Erfassung der Ergebnisse und der Kosten von Versorgungsleistungen für Menschen mit schweren psychischen Erkrankungen.  Gesundheitswesen. 2001;  63 (Sonderheft 1) 27-31
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 29 Lilly. Are people with schizophrenia getting the best treatment?. Lilly 2000
    Google Scholar
  • 30 Linden M, Godemann F, Gaebel W, Köpke W, Müller P, Müller-Spahn F. et al . A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years.  Schizophrenia Bulletin. 2001;  27(4) 585-596
    PubMedGoogle Scholar
  • 31 Lindström E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.  Pharmacoeconomics. 2000;  18(2) 05-124
    PubMedGoogle Scholar
  • 32 McCallum R C, Brown M W. The use of causal indicators in covariance structure models: Some practical issues.  Psychol Bull. 1993;  114(3) 533-541
    CrossrefPubMedGoogle Scholar
  • 33 Moore A, Sellwood W, Stirling J. Compliance and psychological reactance in schizophrenia.  British Journal of Clinical Psychology. 2000;  39 287-295
    CrossrefPubMedGoogle Scholar
  • 34 Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.  Int Clin Psychopharmacol. 1995;  10 Suppl 3 33-138
    PubMedGoogle Scholar
  • 35 National Institute of Mental Health. 12 - CGI. Clinical global impressions. In: Guy W, Bonato RR, editors Manual for the ECDEU assessment battery. 2. rev. ed Maryland; Chevy Chase 1970 : 12-1-12-6
    Google Scholar
  • 36 Oehl M, Hummer M, Fleischhacker W W. Compliance with antipsychotic treatment.  Acta Psychiatr Scand. 2000;  102 83-86
    PubMedGoogle Scholar
  • 37 Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Henderson T J. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol.  Journal of Clinical Psychiatry. 2000;  61 382-386
    PubMedGoogle Scholar
  • 38 Rossi A, Arduini L, Stratta P, Pallanti S. Subjective experience and subjective response to neuroleptics in schizophrenia.  Comprehensive Psychiatry. 2000;  41 446-449
    CrossrefPubMedGoogle Scholar
  • 39 Ruscher S M, de Wit R, Mazmanian D. Psychiatric patients’ attitudes about medication and factors affecting noncompliance.  Psychiatric Services. 1997;  48 82-85
    PubMedGoogle Scholar
  • 40 Sellwood W, Tarrier N. Demographic factors associated with extreme noncompliance in schizophrenia.  Social Psychiatry and Psychiatric Epidemiology. 1994;  29 172-177
    PubMedGoogle Scholar
  • 41 Taylor D, Shapland L, Laverick G ., Bond J, Munro J. Clozapine - a survey of patient perception.  Psychiatr Bull. 2000;  24 450-452
    PubMedGoogle Scholar
  • 42 Tunnicliffe S, Harrison G, Standen P J. Factors affecting compliance with depot injection treatment in the community.  Social Psychiatry and Psychiatric Epidemiology. 1992;  27 230-233
    CrossrefPubMedGoogle Scholar
  • 43 Valenstein M, Copeland L A, Owen R, Blow F C, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia.  Journal of Clinical Psychiatry. 2001;  62 545-551
    PubMedGoogle Scholar
  • 44 Van Putten T, May P R. Subjective response as a predictor of outcome in pharmacotherapy: The consumer has a point.  Arch Gen Psychiatr. 1978;  35 477-480
    PubMedGoogle Scholar
  • 45 Ventura J, Green M F, Shaner A, Lieberman R .P. Training and quality assurance with the brief psychiatric rating scale: ”The Drift Busters”.  Intern Meth Psychiatr Res. 1993;  3 221-244
    PubMedGoogle Scholar
  • 46 Wahlbeck K, Tuunainen A, Ahokas A. Dropout rates in randomised antipsychotic drug trials.  Psychopharmacology. 2001;  155 230-233
    CrossrefPubMedGoogle Scholar
  • 47 Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz L M. et al . Rating of medication influences (ROMI) scale in schizophrenia.  Schizophr Bull. 1994;  20(2) 297-310
    PubMedGoogle Scholar
  • 48 Wolfson P .W., Paton C. Clozapine audit: What do patients and relatives think?.  J Ment Hlth. 1996;  5(3) 267-273
    PubMedGoogle Scholar

Dr. Reinhold Kilian

Department of Psychiatry

University of Leipzig

Johannisallee 20

D-04317 Leipzig

Telefon: 0341/ 97 24 532

Fax: 0341/ 97 24 539

eMail: kilr@medizin.uni-leipzig.de

      >